Saturday, 22 November 2025
  
Login

Australia's most trusted
source of pharma news

Saturday, 22 November 2025
News

$275 blunder opens huge market

 Posted 21 November 2025 PM

Novo Nordisk’s failure to pay a AUD$275 patent maintenance fee has opened up the Canadian semaglutide market to generics – and Sandoz is making the most of it. It has submitted a biosimilar for approval and hopes to launch there next year.

“No one’s actually got an approval yet, but certainly we would expect to see entrance in that market in Q1 [or] Q2 next year,” Sandoz CEO Richard Saynor said at the Financial Times Global Pharma and Biotech Summit last week.

To see the whole article, please login


Latest Jobs
Pharma in Focus  Jobs

Marketing & Communications (2)

Sales & Customer Relations (14)

Clinical & Medical, R&D (5)

Regulatory, Pharmacovigilance & QA (5)

Other (13)

MORE NEWS
Email this article to a friend
From:

 
 
  
Print this article

Copyright Notice

Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.

Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.

Welcome to Pharma in Focus

Please log in to read.

Hi

Our old access system is being retired.

Please create a password and click 'Log in' for ongoing access.

Hi

Please choose a password to secure your access to Pharma in Focus (minimum 8 characters).

Hi

You're here because you requested to reset your password.

Please choose a new password (minimum 8 characters).

To search the News Archive you need to be logged in.

 

You can choose not to do this now but after November 30, a password will be required.

To learn more about the new-look Pharma in Focus click here.